RADAR-AD study finds machine learning and AR-based markers promising for detecting Alzheimer’s | |
Altoida, a frontrunner in harnessing augmented reality and machine learning for neurological conditions, recently unveiled groundbreaking results from the RADAR-AD consortium study. This study, featured in Nature Digital Medicine, delved into Altoida’s augmented reality (AR) and machine learning (ML)-based digital cognitive assessment, striving for early identification of Alzheimer’s disease (AD). The ‘Remote Assessment of Disease and Relapse – Alzheimer’s Disease’ (RADAR-AD) study embarked on an independent validation journey involving 121 participants over 50. Utilizing various remote monitoring technologies (RMTs), including Altoida’s AR digital cognitive and functional assessment, the study aimed to detect cognitive and functional decline in AD. Unlike traditional clinical assessments, RMTs offer objective and frequent monitoring of daily activities, aiding early impairment detection without clinician intervention. The Altoida AR app, comprising motor and AR tasks, underwent evaluation in amyloid beta-negative healthy controls (HC), amyloid beta-positive cognitively normal preclinical AD participants (preAD), and prodromal AD participants (proAD). These tasks involved exercises testing motor skills and AR simulations of complex daily activities. Altoida’s ML model, fueled by data from internal sensors, aimed to differentiate normal from impaired participants. For more details please visit our website - https://www.medhealthinsight.com/new-soundboard-review-pricing-is-not-always-the-only-criteria-2-11-2-131/ ![]() | |
| Related Link: Click here to visit item owner's website (0 hit) | |
| Target State: New York Target City : New work city Last Update : Nov 21, 2025 5:22 AM Number of Views: 11 | Item Owner : medhealthinsight Contact Email: (None) Contact Phone: (None) |
| Friendly reminder: Click here to read some tips. | |